Clinical Trial Update: A Study to Assess the Safety and Immunogenicity of PXVX0317 Chikungunya Virus Virus-Like Particle Vaccine [Phase 2]

View source ↗

Summary

A Phase 2 study assessing safety and immunogenicity of PXVX0317 Chikungunya virus-like particle vaccine has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chikungunya Virus Infection

Drugs mentioned

• PXVX0317 (CHIKV VLP Vaccine)

Snippet

Sponsor: Bavarian Nordic | Conditions: Chikungunya Virus | Phase 2 | Status: COMPLETED | Results posted: 2023-02-28